Management of relapsed/refractory Chronic Lymphocytic Leukemia

por Woyach, Jennifer A.
Publicado 2022

BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL

por Rogers, Andrew, Woyach, Jennifer A.
Publicado 2020

Boosting BNT162b2 vaccine efficacy in CLL

por Bhat, Seema A., Woyach, Jennifer A.
Publicado 2022

Characterization and mitigation of fragmentation enzyme-induced dual stranded artifacts

por Gregory, Thomas, Ngankeu, Apollinaire, Orwick, Shelley, Kautto, Esko A, Woyach, Jennifer A, Byrd, John C, Blachly, James S
Publicado 2020

Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL

por Yano, Max, Nunes, Jessica, Mo, Xiaokui, Rogers, Kerry A., Woyach, Jennifer A., Byrd, John C., Muthusamy, Natarajan
Publicado 2022

Incidence and survival of hematological cancers among adults ages ≥75 years

por Krok‐Schoen, Jessica L., Fisher, James L., Stephens, Julie A., Mims, Alice, Ayyappan, Sabarish, Woyach, Jennifer A., Rosko, Ashley E.
Publicado 2018

Racial and socioeconomic disparities in CLL/SLL: analysis of SEER data from 2006 to 2019

por Kittai, Adam S., Huang, Ying, Bhat, Seema A., Paskett, Electra D., Rogers, Kerry A., Barrientos, Jacqueline C., Fisher, James L., Woyach, Jennifer A.
Publicado 2022

A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

por Woyach, Jennifer A, Lin, Thomas S, Lucas, Margaret S, Heerema, Nyla, Moran, Mollie E., Cheney, Carolyn, Lucas, David M., Wei, Lai, Caligiuri, Michael A., Byrd, John C.
Publicado 2009

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

por Guinn, Daphne, Ruppert, Amy S., Maddocks, Kami, Jaglowski, Samantha, Gordon, Amber, Lin, Thomas S., Larson, Richard, Marcucci, Guido, Hertlein, Erin, Woyach, Jennifer, Johnson, Amy J., Byrd, John C.
Publicado 2014

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

por Muhowski, Elizabeth M., Ravikrishnan, Janani, Gordon, Britten, Yu, Lianbo, Misra, Shrilekha, Walker, Brandi, Eathiraj, Sudharshan, Sampath, Deepa, Rogers, Kerry A., Byrd, John C., Woyach, Jennifer A.
Publicado 2022

Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

por Woyach, Jennifer A., Barr, Paul M., Kipps, Thomas J., Barrientos, Jacqueline C., Ahn, Inhye E., Ghia, Paolo, Girardi, Vincent, Hsu, Emily, Jermain, Mandy, Burger, Jan A.
Publicado 2023

Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes

por Hyak, Jonathan M., Huang, Ying, Rogers, Kerry A., Bhat, Seema A., Grever, Michael R., Byrd, John C., Kittai, Adam S., Jones, Dan, Miller, Cecelia R., Woyach, Jennifer A.
Publicado 2022

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition

por Eisenmann, Eric D., Fu, Qiang, Muhowski, Elizabeth M., Jin, Yan, Uddin, Muhammad Erfan, Garrison, Dominique A., Weber, Robert H., Woyach, Jennifer A., Byrd, John C., Sparreboom, Alex, Baker, Sharyn D.
Publicado 2021

P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES

por Woyach, Jennifer, Flinn, Ian W., Awan, Farrukh, Eradat, Herbert, Brander, Danielle M., Tees, Michael, Parikh, Sameer, Phillips, Tycel, Ghori, Razi, Paydar, Ima, Farooqui, Mohammed Z. H., Byrd, John C., Stephens, Deborah
Publicado 2023

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STU...

por Cohen, Jonathon, Roeker, Lindsey, Cheah, Chan, Eyre, Toby, Patel, Krish, Woyach, Jennifer, Seymour, John, Wang, Michael, Wang, Yucai, Loubert, Angely, Payakachat, Nalin, Hess, Lisa, Abada, Paolo, Mato, Anthony R., Ghia, Paolo
Publicado 2023

The regulation of tumor‐suppressive microRNA, miR‐126, in chronic lymphocytic leukemia

por Guinn, Daphne, Lehman, Amy, Fabian, Catherine, Yu, Lianbo, Maddocks, Kami, Andritsos, Leslie A., Jones, Jeffrey A., Flynn, Joseph M., Jaglowski, Samantha M., Woyach, Jennifer A., Byrd, John C., Johnson, Amy J.
Publicado 2017

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

por Jurczak, Wojciech, Coombs, Catherine C., Shah, Nirav N., Woyach, Jennifer, Cheah, Chan Y., Patel, Krish, Maddocks, Kami, Wang, Yucai, E. Muehlenbein, Catherine, Wang, Chunxiao, Abhyankar, Sarang, Tsai, Donald E., Eyre, Toby A.
Publicado 2023

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six...

por Gopalakrishnan, Sathej, Menon, Rajeev, Suleiman, Ahmed A., Kater, Arnon P., Stilgenbauer, Stephan, Seymour, John F., Chyla, Brenda, Lu, Tong, Young Kim, Su, Roberts, Andrew W., Woyach, Jennifer A., Mensing, Sven, Salem, Ahmed Hamed
Publicado 2023

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

por Chen, Timothy L., Harrington, Bonnie, Truxall, Jean, Wasmuth, Ronni, Prouty, Alexander, Sloan, Shelby, Lehman, Amy M., Sampath, Deepa, Orlemans, Eric, Baiocchi, Robert A., Alinari, Lapo, Byrd, John C., Woyach, Jennifer A., Hertlein, Erin
Publicado 2021

Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia

por Heerema, Nyla A., Muthusamy, Natarajan, Zhao, Qiuhong, Ruppert, Amy S., Breidenbach, Heather, Andritsos, Leslie A., Grever, Michael R., Maddocks, Kami J., Woyach, Jennifer, Awan, Farrukh, Long, Meixiao, Gordon, Amber, Coombes, Caitlin, Byrd, John C.
Publicado 2020